A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV
DOI:
10.1016/j.str.2025.04.016
Publication Date:
2025-05-14T14:37:26Z
AUTHORS (46)
ABSTRACT
Anti-HIV envelope broadly neutralizing antibodies (bnAbs) are alternatives to conventional antiretrovirals with the potential prevent and treat infection, reduce latent reservoirs, and/or mediate a functional cure. Clinical trials "first-generation" bnAbs used alone or in combination show promising antiviral effects but also highlight that additional engineering of "enhanced" will be required for optimal clinical utility, while preserving enhancing Current Good Manufacturing Practices (cGMP) manufacturing capability. Here, we report an anti-CD4-binding site (CD4bs) bnAb, N49P9.3. Through series rational modifications, produced variant, N49P9.6-FR-LS, demonstrates enhanced potency, superior activity other bnAbs, low polyreactivity, longer circulating half-life. Additional final eN49P9, properties conducive cGMP production. Overall, these efforts demonstrate feasibility developing anti-CD4bs greatly improved as well translational value.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (105)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....